Article information
Full text is only aviable in PDF
Bibliografía
[1.]
C.F. Mountain.
Revisions in the international system for staging lung cancer.
Chest, 111 (1997), pp. 1.710-1.717
[2.]
F.G. Pearson, N.C. Delarue, R. Ilves, T.R. Todd, J.D. Cooper.
Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung.
J Thorac Cardiovasc Surg, 83 (1982), pp. 1-11
[3.]
H. Takita, A.C. Hollinshead, D.J. Rizzo, C.M. Kramer, T.Y. Chen, J.N. Bhayana, et al.
Treatment of inoperable lung carcinoma: a combined modality approach.
Ann Thorac Surg, 28 (1979), pp. 363-368
[4.]
S. Taylor, M. Trybula, P. Bonomi, et al.
Simultaneous cisplatin-fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer.
Ann Thorac Surg, 43 (1987), pp. 87-91
[5.]
L.P. Faber, C.F. Kittle, W.H. Warren, P.D. Bonomi, S.G. Taylor IV, S. Reddy, et al.
Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer.
Ann Thorac Surg, 47 (1989), pp. 669-677
[6.]
A. Skarin, Jochel, M. son, T. Sheldon, A. Malcolm, P. Oliynyk, R. Overholt, et al.
Neoadjuvant chemotherapy in marginally resectable stage III MO non-small cell lung cancer: long-term follow-up in 41 patients.
J Surg Oncol, 40 (1989), pp. 266-274
[7.]
P.L. Weiden, S. Piantadosi.
Preoperative chemoradiotherapy in stage III non-small cell lung cancer: a phase II studv of the Lung Cancer Study Group.
J Nat Cancer Inst, 83 (1991), pp. 266-272
[8.]
G.M. Strauss, J.E. Herndon, D.D. Sherman, D.J. Mathisen, R.W. Carey, N.C. Choi, et al.
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a cancer and leukemia group B phase II study.
J Clin Oncol, 10 (1992), pp. 1.237-1.244
[9.]
D.H. Kirn, T.J. Lynch, S.J. Mentzer, T.H. Lee, G.M. Straus, A.D. Elias, et al.
Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer: impact of preoperative chemotherapy on resectability and downstaging.
J Thorac Cardiovasc Surg, 106 (1993), pp. 696-702
[10.]
R. Burkes, R. Ginsberg, F. Shepherd, M.E. Blackstein, M.E. Goldber, P.F. Waters, et al.
Induction chemotherapy with mitomycin C, vindesien and cisplatin for stage 111 unresectable non-small cell lung cancer: results of the Toronto phase II trial.
J Clin Oncol, 10 (1992), pp. 580-586
[11.]
N. Martini, M.G. Kris, B.J. Flehinger, R.J. Gralla, M.S. Bains, M.E. Burt, et al.
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
Ann Thorac Surg, 55 (1993), pp. 1.365-1.373
[12.]
V.W. Rusch, K.S. Albain, J.J. Crowley, T.W. Rice, A.T. Turrisi, J.K. Weick, et al.
Surgical resection of stage IIIA and stage IIIB non-small cell lung cancer after concurrent induction chemotherapy. A Southwest Oncology Group trial.
J Thorac Cardiovasc Surg, 105 (1993), pp. 97-106
[13.]
D.J. Sugarbaker, J. Herndon, L.J. Kohman, M.G. Krasna, M.R. Green.
Results of Cancer and Leukemia Group B Protocol 8935: A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer.
J Thorac Cardiovasc Surg, 109 (1995), pp. 473-485
[14.]
J. Aristu, J. Rebollo, R. Martínez-Monge, J.M. Aramendía, J.C. Viera, I. Azinovic, et al.
Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study.
Am J Clin Oncol, 20 (1997), pp. 276-281
[15.]
J.A.B. Roth, F. Fosella, R. Komaki, M.B. Ryan, J.B. Putnam Jr., J.S. Lee.
A randomized trial comparing perioperative chemotherapy and surgery alone in resectable stage IIIA non-small cell lung cancer.
J Nat Cancer Inst, 86 (1994), pp. 673-680
[16.]
R. Rosell, J. Gómez-Codina, C. Camps, J. Maestre, J. Padilla, A. Cantó, et al.
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in patients with non-small cell lung cancer.
N Engí J Med, 330 (1994), pp. 153-158
[17.]
Non-Small Cell Lung Cancer Colloborative Group.
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials.
Br Med J, 311 (1995), pp. 899-909
[18.]
D. Ukena, M. Leutz, H. Huwer, H.J. Schäfers, G.W. Sybrecht.
Induction chemotherapy in locally advanced stage IIIA/IIIB non-small cell lung cancer (NSCLC): paclitaxel/carboplatin vs. Mitomycin C/ifosfamide/cisplatin (MlC)..
EurRespirJ, 10 (1997), pp. 154
[19.]
V.W. Rusch.
Resection of stage III non-small cell lung cancer following induction therapy.
World J Surg, 19 (1995), pp. 817-822
[20.]
S. El Rouby, A. Thomas, D. Costin, C.R. Rosenberg, M. Potmesil, R. Silber, et al.
p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is dependent of MDR1/MDR3 gene expression.
Blood, 82 (1993), pp. 3.452-3.459
[21.]
R. Rosell, A. Font, A. Pifarré, M. Canela, J. Maurel, A. Arellano, et al.
The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC.
Chest, 109 (1996), pp. 102-106
[22.]
M. Tonato.
The role of neoadjuvant chemotherapy in NSCLC.
Chest, 109 (1996), pp. 93-95
[23.]
J.P. Van Meerbeeck, J.F. Vansteenkiste, P.E.Y. Van Schil, P. Weynants, G. Scagliotti, S. Darwish, et al.
Neoadjuvant chemotherapy followed by surgical resection or thoracic radiotherapy in stage IIIA-N2 non-small cell lung cancer: a multicentric randomized European experience.
Eur Respir J, 10 (1997), pp. 153
[24.]
T.A.W. Spiinter.
Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
Semin Oncol, 16 (1996), pp. 59-61
Copyright © 1998. Sociedad Española de Neumología y Cirugía Torácica
